<DOC>
	<DOCNO>NCT00721305</DOCNO>
	<brief_summary>The purpose study determine whether long-term administration statin may benefit clinical immunological evolution HIV-1-infected individual use antiretroviral therapy require .</brief_summary>
	<brief_title>Lovastatin : Immunomodulatory Value Evaluation</brief_title>
	<detailed_description>Despite fact HAART produce decrease HIV-1 replication plasma HIV-1 RNA level , allow increase CD4 T-cell count lead diminution incidence opportunistic infection mortality , cost complexity HAART regimens , grow list long-term side effect , eventual development resistance underscore immediate need additional therapeutic approach . Statins exert pleiotropic effect variety mechanism , among several immunological effect relate unrelated cholesterol-lowering activity . HIV-1 require cholesterol lipid raft several key stage replication cycle ; statins-mediated depletion cholesterol alters capacity cell form lipid rafts decrease HIV-1 infectivity . On hand , statin may exert significant modulator effect balance cytokine network , alter activity Rho GTPases LFA-1 ICAM-1 adhesion molecule . Preliminary study show statin ( Lovastatin ) anti HIV-1 activity , administration safe efficient control HIV-1 infection chronically infected individual receive HAART ( term decrease viral load increase CD4 T-cell count ) . Because limited clinical data available topic , study conduct .</detailed_description>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Asymptomatic HIV1 seropositive individual , age ≥ 18 year , HAART naive HIV1 infection confirm : positive Westernblot test date least six month admission study ; Westernblot test within last six month , also positive p31 p66 band Detectable viral load &lt; 100,000 copies/ml CD4+ T cell count ≥ 350 cells/ul Inability unwillingness patient give write informed consent . Main residence outside Medellin metropolitan area , indication difficulty followup period Participation clinical trial Evidence patient exhibit low adherence intervention followup ( MoriskyGreen test ) Pregnancy breastfeed Any type antiretroviral treatment admission study , therapy lipidlowering drug last six month Antecedents allergy , contraindication intolerance statin Patients receive medication generate relevant interaction lovastatin : clarithromycin , erythromycin , azithromycin , itraconazole , ketoconazole , nefodozone , cimetidine , rifampin , phenobarbital , carbamazepine , phenytoin . Unwillingness avoid consumption Citrus paradise ( grapefruit juice ) Saint John 's Wort ( Hypericum ) Opportunistic infection type AIDSdefining disease Chronic active hepatitis ( B C ) Any hepatocellular disease , indicated elevation liver enzyme ( AST ALT ) twice reference value Renal failure , indicate serum creatinine ≥ 2 mg/dl Myopathy , indicate elevation creatine phosphokinase ( CPK ) five time reference value Infection acute disease require inpatient treatment Active substancerelated disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Type 1 human immunodeficiency virus infection</keyword>
	<keyword>Lovastatin</keyword>
	<keyword>Adaptive Immunity</keyword>
	<keyword>Cellular cholesterol</keyword>
	<keyword>Rho GTPases</keyword>
	<keyword>Lymphocyte function-associated antigen-1</keyword>
</DOC>